Prenatal and Infant Exposure to Thimerosal From Vaccines and Immunoglobulins and Risk of Autism.  Price, CS. et. al.  Pediatrics 2010;126:656-664.

Comments by SafeMinds

Background

This study was funded by CDC and conducted by several parties with an interest in protecting vaccine use: CDC staff involved in vaccine research and promotion; Abt Associates, a contract research organization whose largest clients include vaccine manufacturers and the CDC's National Immunization Program; America's Health Insurance Plans, the trade group for the health insurance industry; and three HMOs which receive substantial funding from vaccine manufacturers to conduct vaccine licensing research. Planning for this study began in 2001. Over the 9 year study period, the large external panel of consultants providing input to the investigators was reduced to a small subset by study end. The original large panel recommended against the study design ultimately employed, as insufficient to answer the question of early thimerosal exposure and autism rates. The CDC and AHIP overruled the external consultants. The paper published this week in Pediatrics reported the curious finding that increased mercury exposure from thimerosal in vaccines actually decreased the risk of having an autism diagnosis.

Study Limitations

There are two primary deficiencies in the study methodology which would lead to the curious finding of a protective, rather than a harmful effect of early thimerosal exposure found in the study. The first deficiency concerns the variables used for stratification and the second concerns the low participation rate leading to sample bias. The stratification scheme would bias the results to the null; the sampling bias would swing the results to show a lower autism rate among those highly exposed. Had these deficiencies been addressed through a better study design, it is equally likely that the results would have in fact shown a harmful effect from early thimerosal exposure.

Exposure variable

The study sample did not allow an examination of an exposed versus an unexposed group, or even a high versus a low exposed group, but rather the study mostly examined the effect of timing of exposure on autism rates.  There were virtually no subjects who were unvaccinated and few who were truly less vaccinated; rather, the low exposed group was mostly just late relative to the higher exposed group, ie, those vaccinating on time.

Another validity problem is the effect on exposure variation of stratifying/matching by birth year and HMO. No reason was provided for matching based on year of birth since the long follow up period allowed sufficient time for all cases to be diagnosed. The matching requirements lead to two statistical problems.

• a. Each of the three HMOs would buy in bulk the same vaccines for all its patients and the promotion of a new vaccine would tend to be uniform across an HMO, so that within an HMO, exposure variability is lessened. Additionally, the recommended vaccines, the formulations offered by manufacturers, and the uptake rate of new vaccines varied by year, so that within a given year, exposure variability is further reduced. The effect is that children in a given year in a given HMO would tend to receive the same vaccines. Thus the stratification scheme is related to the exposure level and would reduce exposure differences in a stratum, weakening the signal. While the exposures to thimerosal may have varied across the study as a whole, the variability within the strata was likely to be low.
• b. The variables of time and place (HMO) are correlated with the exposure variable. Statistically, the correlation would reduce the effect of the exposure variable, as the two matching variables compete with the exposure variable to explain differences in the autism outcome. For example, say for simplicity that HMO A used vaccines in 1994 which exposed all enrolled infants up to 6 months of age with 75 mcg of mercury; the rate of ASD for 1994 births in HMO A was found to be 1 in 150. In 1995, HMO A used vaccines which exposed all enrolled infants up to 6 months of age to 150 mcg of mercury; the rate of ASD for these children rises to 1 in 100. By stratifying by year for this HMO, those children born in 1994, whether or not they had an ASD, would show identical exposures. Those with an ASD born in 1995 in HMO A would also have the same exposures as those born in 1995 in HMO A without an ASD. The association between the increased exposure and the increase in ASD can only be detected by removing the birth year variable, which otherwise masks the effect of exposure on outcomes.

Sample bias